About ISCARE a.s.
"Klinické centrum ISCARE a.s.. poskytuje specializované lékařské výkony již od roku 1995. Najdete u nás centrum reprodukční medicíny, klinické a výzkumné centrum pro střevní záněty, centrum jednodenní chirurgie, centrum ortopedie, centrum revmatologie, centrum andrologie a centrum žilní chirurgie."
- Top Sponsors
- Top Collaborators
- Trials By Phase
- Recruitment Status
- Top Conditions
- Intervention Types
- Top Intervention Names
- Trials By Gender
Lead Sponsor
# Trials
Hoffmann-La Roche
6
Celgene
5
Janssen Research & Development, LLC
5
Eli Lilly and Company
4
Janssen-Cilag Ltd.
3
Shire
3
Arena Pharmaceuticals
2
Takeda
2
Janssen Scientific Affairs, LLC
1
Pfizer
1
Clinical Trials at ISCARE a.s.
During the past decade, ISCARE a.s. conducted 28 clinical trials. In the 10-year time frame, 28 clinical trials started and 14 clinical trials were completed, i.e. on
average, 50% percent of trials that started reached the finish line to date. In the past 5 years, 5 clinical trials started and 13 clinical trials were completed. i.e. 260%
of trials that started reached the finish line.
Trials List
Trail ID
Brief Title
Start Date
Completion Date
Status
Enrollment
A Study of the Efficacy and Safety of Etrolizumab in Participants With Ulcerative Colitis Who Have Been Previously Exposed to Tumor Necrosis Factor (TNF) Inhibitors
2014-05-21
2020-04-16
Completed
609
Study for Participants With Ulcerative Colitis Previously Enrolled in Etrolizumab Phase II/III Studies
2014-09-15
2025-08-16
Active, not recruiting
1,822
A Study Comparing the Efficacy and Safety of Etrolizumab to Infliximab in Participants With Moderate to Severe Ulcerative Colitis Who Are Naïve to Tumor Necrosis Factor (TNF) Inhibitors
2014-12-24
2020-06-23
Completed
397
A Study Comparing the Efficacy and Safety of Etrolizumab With Adalimumab and Placebo in Participants With Moderate to Severe Ulcerative Colitis (UC) in Participants Naive to Tumor Necrosis Factor (TNF) Inhibitors
2014-11-14
2020-05-25
Completed
358
A Study to Assess Whether Etrolizumab is a Safe and Efficacious Treatment for Participants With Moderately to Severely Active Crohn's Disease
2015-03-20
2021-09-07
Completed
1,035
Open-Label Extension and Safety Study for Participants With Crohn's Disease Previously Enrolled in the Etrolizumab Phase III Study GA29144
2015-06-08
2026-05-21
Active, not recruiting
900
Safety and Efficacy Trial of RPC1063 for Moderate to Severe Ulcerative Colitis
2015-06-17
2020-06-17
Completed
1,012
An Efficacy and Safety Study of Vedolizumab Intravenous (IV) Compared to Adalimumab Subcutaneous (SC) in Participants With Ulcerative Colitis
2015-06-29
2019-01-18
Completed
771
Clinical Trials Sponsors and Collaborators
Out of the total clinical trials conducted in "ISCARE a.s." #1 sponsor was "Hoffmann-La Roche" with 6 trials, followed by "Celgene" with 5 trials
sponsored, "Janssen Research & Development, LLC" with 5 trials sponsored, "Eli Lilly and Company" with 4 trials sponsored and "Janssen-Cilag Ltd."
with 4 trials sponsored. Other sponsors include 4 different institutions and
companies that sponsored additional 10 trials in total.
In terms of collaborators to trials, out of the total clinical trials conducted in "ISCARE a.s."
#1 collaborator was "Arena is a wholly owned subsidiary of Pfizer" with 1 trials as a collaborator. Other collaborators include -1 different institutions and companies that were
collaborators in the rest 1 trials.
Clinical Trials Conditions at ISCARE a.s.
According to Clinical.Site data, the most researched conditions in "ISCARE a.s." are
"Ulcerative Colitis" (16 trials), "Crohn Disease" (9 trials), "Colitis, Ulcerative" (4 trials), "Crohn's Disease" (4 trials) and "Fistulizing Crohns Disease" (1 trials). Many other conditions were trialed in "ISCARE a.s." in a lesser frequency.
Clinical Trials Intervention Types at ISCARE a.s.
Most popular intervention types in "ISCARE a.s." are "Drug" (31 trials), "Other" (7 trials) and "Biological" (3 trials). Other intervention types were less common.
The name of intervention was led by "Placebo" (17 trials), "Etrolizumab" (5 trials), "Guselkumab" (5 trials), "Etrasimod" (3 trials) and "Mirikizumab" (3 trials). Other intervention names were less common.
Clinical Trials Genders at ISCARE a.s.
The vast majority of trials in "ISCARE a.s." are
32 trials for "All" genders.
Clinical Trials Status at ISCARE a.s.
Currently, there are NaN active trials in "ISCARE a.s.".
undefined are not yet recruiting,
10 are recruiting,
8 are Active, not recruiting,
and undefined are Enrolling by invitation.
In total, there were 13 completed trials in ISCARE a.s.,
undefined suspended trials,
and 1 terminated clinical trials to date.
Out of the total trials that were conducted in ISCARE a.s., 0 "Phase 1"
clinical trials were conducted, 4 "Phase 2" clinical
trials and 29 "Phase 3" clinical trials were conducted as
well. "Phase 4" trials included 1 trials, and there were
also 0 trials that are defined as “Not Applicable".
Departments of ISCARE a.s.
ISCARE a.s. has several departments that took part in Clinical trials: "ISCARE a.s. (Klinicke centrum ISCARE), Klinicke a vyzkumne centrum pro strevni zanety" - 3 trials
Departments List
Name
City
Trials